Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
M. Venturini, Andrea Michelotti, Lucia Del Mastro et al. · Journal of Clinical Oncology · 1996
PURPOSE: Dexrazoxane was found effective in reducing doxorubicin cardiotoxicity when given at a dose ratio (dexrazoxane: doxorubicin) of 20:1. Preclinical studies indicated that dexrazoxane at a dose ratio of 10 to 15:1 also protected against epirubicin-induced cardiotoxicity. The main objective of this study was to investigate the efficacy of dexrazoxane, given at a dose ratio of 10:1 against epirubicin cardiotoxicity. PATIENTS AND METHODS: One hundred sixty-two advanced breast cancer patients were randomized to receive epirubicin-based chemotherapy with or without dexrazoxane. Patients who had previously received adjuvant chemotherapy that contained anthracyclines were treated with cyclophosphamide 600 mg/m2 intravenously (IV), epirubicin 60 mg/m2 IV, and fluorouracil 600 mg/m2 IV, on day 1 every 3 weeks. The other patients were treated with epirubicin 120 mg/m2 IV on day 1 every 3 weeks. Cardiac toxicity was defined as clinical signs of congestive heart failure, a decrease in resting left ventricular ejection fraction (LVEF) to < or = 45%, or a decrease from baseline resting LVEF of > or = 20 EF units. RESULTS: One hundred sixty patients were evaluated. Cardiotoxicity was recorded in 18 of 78 patients (23.1%) in the control arm and in six of 82 (7.3%) in the dexrazoxone arm. The cumulative probability of developing cardiotoxicity was significantly lower in dexrazoxane-treated patients than in control patients (P = .006; odds ratio, 0.29; 95% confidence limit [CL], 0.09 to 0.78). Noncardiac toxicity, objective response, progression-free survival, and overall survival were similar in both arms. CONCLUSION: Dexrazoxane given at a dexrazoxane:epirubicin dose ratio of 10:1 protects against epirubicin-induced cardiotoxicity and does not affect the clinical activity and the noncardiac toxicity of epirubicin. The clinical use of dexrazoxane should be recommended in patients whose risk of developing cardiotoxicity could hamper the eventual use and possible benefit of epirubicin.
Cited by 165 works. doi:10.1200/jco.1996.14.12.3112
Authors
- M. Venturini
- Andrea Michelotti
- Lucia Del Mastro
- Flavio Carnino
- Ornella Garrone
- Carmelo Tibaldi
- Nicola Molea
- Riccardo C. Bellina
- Paolo Pronzato
- P. Cyrus
- J. Vinke
- Franco Testore
- M Guelfi
- Rita Lionetto
- Paolo Bruzzi
- PierFranco Conte
- Renzo Rosso
References
- Reporting results of cancer treatment
- Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
- Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
- Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
- Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation.
- A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
- Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
- Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma